August 25, 2021
Leaky Gut Syndrome A 34-year-old female with IBS symptoms and post-antibiotic dysbiosis completed a 90-day low-dose protocol (0.3mg daily), with notable improvement in bloating, bowel regularity, and gut-related fatigue
In physiciansupervised settings, BPC157 and TB500 have shown favorable safety profiles in preclinical and early clinical use, with most side effects being mild and transient (such as temporary injectionsite irritation or mild digestive changes)
All supporting evidence derives from separate preclinical studies of individual peptides in different animal models, injury types, and administration routes
They should attend regular follow-up appointments and report any new or worsening neurological symptoms promptly
TB-500 provides broader systemic healing effects, promoting cell migration throughout the body and enhancing flexibility of tissue structures